A phase I trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study.

[1]  J. Kwon,et al.  A phase II study of bevacizumab in combination with definitive radiotherapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma: preliminary results of RTOG 0417. , 2012, International journal of radiation oncology, biology, physics.

[2]  P. Petrow,et al.  CETUXICOL, a phase II trial randomizing standard treatment with or without cetuximab in primary cervical cancer treatment. , 2012 .

[3]  P. Fracasso,et al.  A phase I study of concurrent weekly topotecan and cisplatin chemotherapy with whole pelvic radiation therapy in locally advanced cervical cancer: a gynecologic oncology group study. , 2012, Gynecologic oncology.

[4]  Jubilee Brown,et al.  Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. , 2011, Gynecologic oncology.

[5]  A. Dueñas-González,et al.  Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Birrer,et al.  Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study. , 2011, Gynecologic oncology.

[7]  J. Vermorken,et al.  Cetuximab in the treatment of squamous cell carcinoma of the head and neck , 2011, Expert review of anticancer therapy.

[8]  S. J. Henley,et al.  Surveillance of screening-detected cancers (colon and rectum, breast, and cervix) - United States, 2004-2006. , 2010, Morbidity and mortality weekly report. Surveillance summaries.

[9]  B. Monk,et al.  Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  B. Monk,et al.  Anti-angiogenesis agents in metastatic or recurrent cervical cancer. , 2010, Gynecologic oncology.

[11]  R. Mannel,et al.  A Phase II Trial of Erlotinib in Recurrent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study , 2009, International Journal of Gynecologic Cancer.

[12]  J. Lee,et al.  Dose Escalation Methods in Phase I Cancer Clinical Trials , 2009, Journal of the National Cancer Institute.

[13]  B. Weber,et al.  Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: A phase II GINECO trial. , 2009, Gynecologic oncology.

[14]  J. Thigpen.  Phase II Trial of Bevacizumab in the Treatment of Persistent or Recurrent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study , 2009 .

[15]  Joan L. Walker,et al.  A phase I/II study of extended field radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in patients with cervical carcinoma metastatic to the para-aortic lymph nodes: a Gynecologic Oncology Group study. , 2009, Gynecologic oncology.

[16]  D. Alberts,et al.  Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  C. Ferreira,et al.  Phase I Trial of Erlotinib Combined with Cisplatin and Radiotherapy for Patients with Locally Advanced Cervical Squamous Cell Cancer , 2008, Clinical Cancer Research.

[18]  C. Bokemeyer,et al.  Platinum-based chemotherapy plus cetuximab in head and neck cancer. , 2008, The New England journal of medicine.

[19]  P. Viens,et al.  A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer. , 2008, Gynecologic oncology.

[20]  P. Rose,et al.  A phase I study of gemcitabine followed by cisplatin concurrent with whole pelvic radiation therapy in locally advanced cervical cancer: a Gynecologic Oncology Group study. , 2007, Gynecologic oncology.

[21]  J. Thigpen,et al.  Long-Term Follow-Up of a Randomized Trial Comparing Concurrent Single Agent Cisplatin, Cisplatin-Based Combination Chemotherapy, or Hydroxyurea During Pelvic Irradiation for Locally Advanced Cervical Cancer: A Gynecologic Oncology Group Study , 2007 .

[22]  P. Grigsby,et al.  An exploratory pharmacogenomic study of neoadjuvant cetuximab (C225, ERBITUX®) followed by cisplatin, radiotherapy, and cetuximab in women with untreated advanced cervical cancer , 2007 .

[23]  A. Dicker,et al.  A Phase II study of acute toxicity for Celebrex (celecoxib) and chemoradiation in patients with locally advanced cervical cancer: primary endpoint analysis of RTOG 0128. , 2005, International journal of radiation oncology, biology, physics.

[24]  Joan L. Walker,et al.  Radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in cervical carcinoma limited to the pelvis: a phase I/II study of the Gynecologic Oncology Group. , 2006, Gynecologic oncology.

[25]  Christopher U. Jones,et al.  Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. , 2006, The New England journal of medicine.

[26]  Yong Bae Kim,et al.  P63 and EGFR as prognostic predictors in stage IIB radiation-treated cervical squamous cell carcinoma. , 2003, Gynecologic oncology.

[27]  Young Tae Kim,et al.  Correlation between expression of EGFR and the prognosis of patients with cervical carcinoma. , 2002, Gynecologic oncology.

[28]  B N Bundy,et al.  Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  T R Fleming,et al.  One-sample multiple testing procedure for phase II clinical trials. , 1982, Biometrics.

[30]  G. Elfring,et al.  Multiple-stage procedures for drug screening. , 1973, Biometrics.